<DOC>
	<DOCNO>NCT02227459</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability multiple dose ND-L02-s0201 subject moderate extensive hepatic fibrosis .</brief_summary>
	<brief_title>Phase 1b/2 , Open Label , Repeat Dose , Dose Escalation Study ND-L02-s0201 Injection Subjects With Moderate Extensive Fibrosis ( METAVIR F3-4 )</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>1 . Male female 18 75 year 2 . Diagnosis METAVIR F34 hepatic fibrosis determine liver biopsy do within 12 month screen ( Cohort 1 ) predose biopsy within 6 week treatment ( Cohorts 2 3 ) 3 . Adequate stable synthetic hepatic function ( albumin ≥ 3 g/dL , international normalize ratio [ INR ] ≤ 1.4 x upper limit normal [ ULN ] stable prior medical history ) . 4 . Adequate stable hepatic function measure alkaline phosphatase ( ALP ) , alanine transaminase ( ALT ) , aspartate transaminase ( AST ) , gamma glutamate transferase ( GGTP ) , total bilirubin ( ALT/AST ≤ 5 x ULN , ALP ≤ 4 x ULN , GGTP ≤ 4 x ULN , bilirubin ≤ 2x ULN stable prior medical history ) . 5 . Platelet count ≥ 75,000/mm3 , hemoglobin ≥ 10 g/dL , white blood cell count ( WBC ) &gt; 3000/µL . 6 . No sign decompensated liver disease ( ascites , hepatic encephalopathy , variceal bleeding ) . 7 . No clinically significant abnormality 12lead electrocardiogram ( ECG ) . 8 . No intercurrent medical condition infection consider clinically significant Investigator . 9 . Clinical laboratory assessment within laboratory limit normal value consider clinically significant Investigator . 10 . Vitamin A level screen must less equal upper limit normal ( ULN 95 µg/dL 3.32 µmol/L ) . 11 . Any male subject , sexually active , agree use barrier contraceptive technique define protocol . If female , subject must nonchildbearing potential define protocol . 12 . Subjects active substance abuser may enrol discretion Principal Investigator . 13 . Willing able provide write informed consent comply study procedure visit schedule , include follow visit . 1 . Any disease condition , opinion Investigator , might compromise hematologic , cardiovascular , pulmonary , renal , gastrointestinal , hepatic , skeletal , central nervous system ; condition may interfere absorption , distribution , metabolism , excretion ND L02 s0201 , would place subject increase risk . 2 . On ongoing therapy HCV/HBV , receive therapy HCV/HBV within 12 week prior administration study drug . 3 . On interferon therapy disease receive interferon therapy disease within 12 week prior administration study drug . 4 . History bone disease , include osteoporosis osteomalacia , Paget 's disease bone , history unexplained fracture fracture minimal trauma . 5 . Alphafetoprotein ( AFP ) ≥ 50 ng/mL sign abnormality hepatocellular carcinoma ultrasound survey liver . 6 . Carcinoembryonic antigen ( CEA ) level ULN . 7 . Laboratory test result include abnormal value consider clinically significant Investigator . 8 . Participated concurrent interventional study last intervention occur within 12 week prior administration study drug . 9 . Taken vitamin A vitamin D supplement multivitamins contain vitamin A vitamin D screen visit administration study drug . 10 . History , within last 2 year , alcohol abuse , significant mental illness , physical dependence opioid . 11 . Veins unsuitable repeated venipuncture IV infusion ( eg , vein difficult locate , access puncture ; vein tendency rupture puncture ) . 12 . Received recent treatment alternative therapy , , opinion Investigator , could potentially confound clinical laboratory assessment . 13 . Lost 500 mL blood within 56 day prior administration study drug . 14 . Body mass index ( BMI ) &gt; 38 kg/m2 . 15 . History human immunodeficiency virus ( HIV ) acquire immunodeficiency syndromerelated illness ( AIDS ) . 16 . History malignancy within last 5 year exception basal cell carcinoma . 17 . Woman childbearing potential . 18 . History hypersensitivity H2receptor antagonists . 19 . Any reason , opinion Investigator Sponsor 's Medical Monitor , make subject unsuitable enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>